AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$ATS

ATS Corp (ATS) (Q2 2027) Earnings Call Highlights: Record Life Sciences Backlog

ATS Corp reported Q2 2027 earnings with a 12.7% YoY increase in order bookings to $827M, driven by Life Sciences. Life Sciences backlog hit a record $1.2B. However, revenues fell 8.6% YoY to $666M, and margins contracted. The company expects $65-75M in annualized savings from cost cuts. Free cash flow improved significantly. Nuclear and SMR opportunities are advancing, but Section 338 tariffs delayed packaging orders, impacting full-year outlook.

Original reporting
finance.yahoo.com
Published Nov 13, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 1:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ATS Corp (ATS) (Q2 2027) Earnings Call Highlights: Record Life Sciences Backlog — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ATSBearishHigh
01

Why it matters

The earnings miss is likely to trigger short‑term price decline, but the record backlog and cost‑saving initiatives provide a longer‑term catalyst.

02

Market read

First‑report earnings data for ATS; material numbers and guidance affect trader decisions today.

03

What to watch

Fixed‑cost program targeting $65‑$75M savings and SMR/nuclear expansion may support longer‑term margins.

Relevance 8/10Novelty 8/10Timing: after‑hours earnings release

Background

ATS Corp released its Q2 2027 earnings call transcript, highlighting both positive order growth and negative revenue/margin trends.

Company-level read

Ticker impact

$ATSBearishHigh confidence
Context

Q2 2027 earnings show revenue down 8.6% to $666M, adjusted earnings down 27.4%, but record life‑sciences backlog of $1.2B and 12.7% booking growth.

Expected impact

likely pressure as investors price in the revenue decline despite backlog growth

Evidence & confidence

Revenue miss is material and fresh; market will react to lower top‑line while weighing future upside from backlog.

Market effects

Sector

Life‑sciences equipment sector may see mixed sentiment as backlog growth is offset by near‑term revenue weakness.

Regional

U.S. biotech and industrial equipment stocks could face short‑term pullback.

Global

Limited to ATS and peers; no broad macro impact.

Counterpoint

What could challenge this read

Backlog record suggests multi‑quarter revenue upside; investors could view the miss as a buying opportunity.

Key entities

  • Executive
    Doug Wright

    CEO of ATS Corp, provided commentary on backlog and SMR opportunities.

  • Executive
    Anne Szywolski

    Interim CFO, discussed fixed‑cost savings and margin outlook.

Read at source← All news

Related articles

$ATSMedAI 8/10

ATS Corp (ATS) Q2 2027 Earnings Call Transcript

ATS Corp reported Q2 2027 order bookings of $827 million and revenue of $666 million, with adjusted earnings of $57 million. Life sciences backlog hit a record $1.2 billion, driven by radiopharma and medical device growth. Energy backlog was $236 million, supported by nuclear and data center investments. The company repurchased 2.2 million shares for $61 million. Q3 revenue is expected to range from $640 million to $680 million, with margin expansion delayed due to lower volumes and mix.

finance.yahoo.com
$ATSHigh

ATS Corporation reports Q2 earnings miss, cuts guidance

ATS Corporation (TSX:ATS, NYSE:ATS) reported Q2 fiscal 2027 earnings below expectations, with adjusted EPS of $0.27 and revenue of $665.8 million, down 8.6% YoY. The company withdrew its full-year guidance, citing delays in non-life sciences businesses and tariff impacts. Q3 revenue is expected to be $640M-$680M. Order Bookings rose 12.7% YoY to $827M, led by life sciences.

investing.com
$ATSMedAI 8/10

ATS (ATS) Q1 2027 Earnings Call Transcript

ATS Corporation reported Q1 fiscal 2027 results on Aug. 6, 2026. Adjusted revenue was $698 million, down 5% y/y, and adjusted EPS was $0.35. Adjusted earnings from operations fell 13.4% to $68.1 million. Order backlog was $1.9 billion and Q2 revenue guidance was $660 million to $700 million. ATS also outlined an 18-month transformation program and $70m to $90m capex guidance.

fool.com
$ATSMed

ATS Q1 Earnings Call Highlights

ATS said it will consolidate some European facilities and shift technical capabilities to sites with capacity. Management expects the first phase to deliver about CAD 20 million in annualized savings, about 30% of the total fixed-cost program (CAD 60-70 million). Q1 restructuring costs were CAD 5.7 million and non-cash charges CAD 21.5 million. ATS guided Q2 revenue to CAD 660-700 million.

yahoo.com